<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043444</url>
  </required_header>
  <id_info>
    <org_study_id>1255501</org_study_id>
    <secondary_id>PHRC 2012</secondary_id>
    <nct_id>NCT02043444</nct_id>
  </id_info>
  <brief_title>Secretory Azoospermia and FDG (Fluoro Deoxyglucose) PET-CT</brief_title>
  <acronym>AzoPredHisto</acronym>
  <official_title>Comparison of FDG PET-CT Estimated Testis Functional Value Between Patients Having Positive Testicular Sperm Cells Extraction and Patients With a Negative Extraction, in Men With Azoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare FDG PET-CT parameters between azoospermia patients having an extraction of sperm
      cells by positive testicular extraction and those with a negative extraction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One third of infertilities is of exclusive male origin and one third of mixed origin
      (presence of a male factor). Ten percent of infertile male have azoospermia with a secretory
      origin in most of cases. Surgical extraction of spermatozoa from testicle is the unique
      possibility to increase the chance for these men to have children using in vitro
      fecundation. However, surgical extraction of spermatozoa is successful in 50% of these
      patients. To date, none of the methods for exploration of male fertility (spermogram,
      hormonal investigation - with dosage of FSH (follicle stimulating hormone) and inhibin B -
      and scrotal ultrasound) can predict the success of surgical sperm cells extraction. We also
      miss the prognostic markers of the testicular function recovery after sterilizing treatments
      (chemotherapy, radiotherapy). The presence of GLUT3 (glucose) transporters, which are
      responsible for the fluoro deoxyglucose uptake, has been reported in seminiferous tubules.
      We have previously shown in a pilot study on a population of men without testis cancer that
      FDG PET-CT parameters - including the standardized uptake value mean, the standardized
      uptake value  max, and the functional testicular volume - were correlated with the
      parameters of spermogram (sperm count, motility, vitality). These findings open the way to
      investigations on the role of the FDG PET-CT in evaluation of secretory azoospermia
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>measure of standardized uptake value (SUV)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison between functional volume with PET exam and volume obtained by scrotal echography</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>comparison functional volume with FSH and inhibin</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>secretory azoospermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>110 men with secretory azoospermia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>excretory azoospermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 men with secretory azoospermia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normospermia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 men with secretory azoospermia</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FDG PET-CT</intervention_name>
    <arm_group_label>secretory azoospermia</arm_group_label>
    <arm_group_label>excretory azoospermia</arm_group_label>
    <arm_group_label>normospermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        absence of sperm cells on 2 spermograms in 3 months interval testicular size has to be
        determined in order to categorized in a group to accept surgery-

        Exclusion Criteria:

        allergy to fluoro deoxyglucose clinical varicocele
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric HUYGHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric HUYGHE, MD</last_name>
    <phone>0033561771041</phone>
    <email>huyghe.e@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrice NJOMNANG, PhD</last_name>
    <phone>0033561771041</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UHBordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henri CLERMONT GALLERANDE, MD</last_name>
      <phone>0033556795540</phone>
      <email>henri.de-clermont-gallerande@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Henri CLERMONT GALLERANDE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Marc RIGOT, MD</last_name>
      <phone>0033320446793</phone>
      <email>jean.marc.rigot@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Marc RIGOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis SIBERT, MD</last_name>
      <phone>0033232888173</phone>
      <email>louis.sibert@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Louis SIBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HUYGHE, MD</last_name>
      <phone>0033561771041</phone>
      <email>huyghe.e@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Patrice NJOMNANG, PhD</last_name>
      <phone>0033561771041</phone>
    </contact_backup>
    <investigator>
      <last_name>Eric HUYGHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ferretti L, Sargos P, Gross-Goupil M, Izard V, Wallerand H, Huyghe E, Rigot JM, Durand X, Benoit G, Ferriere JM, Droupy S. Testicular-sparing surgery for bilateral or monorchide testicular tumors: a multicenter study of long term oncological and functional results. BJU Int. 2013 Nov 1. doi: 10.1111/bju.12549. [Epub ahead of print]</citation>
    <PMID>24180380</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azoospermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
